Primary Peritoneal clinical trials at UCLA
1 in progress, 0 open to eligible people
Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Sorry, in progress, not accepting new patients
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
Los Angeles, California and other locations
Our lead scientists for Primary Peritoneal research studies include Sanaz Memarzadeh.